John Martin Gibson

John Martin Gibson

Auto-generated profile, based on publicly available information

John Martin Gibson

The School of Medicine and Manchester Academic Health Sciences Centre, Manchester University, Manchester M13 9PL, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in The Lancet
Verified
Journal Article
Closed access
MSManjinder S Sandhu
Manjinder S Sandhu
AHAdrian H Heald
Adrian H Heald
JGJ Martin Gibson
J Martin Gibson
JCJ Kennedy Cruickshank
J Kennedy Cruickshank
DDDavid Dunger
David Dunger
NWNicholas J Wareham
Nicholas J Wareham

29 September 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JVJørgen Vestbo
Jørgen Vestbo
DLDavid Leather
David Leather
NBNawar Diar Bakerly
Nawar Diar Bakerly
JNJohn New
John New
JGJ. Martin Gibson
J. Martin Gibson
AWAshley Woodcock
Ashley Woodcock
Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice. In a controlled effectiveness trial conducted in 75 general practices, we randomly assigned 2799 patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate–vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care professional) and secondary care contact (inpatient admission, outpatient visit with a specialist, or visit to the emergency department), modification of the initial trial treatment for COPD, and the rate of exacerbations among patients who had had an exacerbation within 3 years before the trial, as assessed in a time-to-event analysis. The rate of moderate or severe exacerbations was significantly lower, by 8.4% (95% confidence interval, 1.1 to 15.2), with fluticasone furoate–vilanterol therapy than with usual care (P=0.02). There was no significant difference in the annual rate of COPD-related contacts to primary or secondary care. There were no significant between-group differences in the rates of the first moderate or severe exacerbation and the first severe exacerbation in the time-to-event analyses. There were no excess serious adverse events of pneumonia in the fluticasone furoate–vilanterol group. The numbers of other serious adverse events were similar in the two groups. In patients with COPD and a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a lower rate of exacerbations than usual care, without a greater risk of serious adverse events. (Funded by GlaxoSmithKline; Salford Lung Study ClinicalTrials.gov number, NCT01551758.)

1 August 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JSJukka T. Salonen
Jukka T. Salonen
PUPekka Uimari
Pekka Uimari
JAJuha-Matti Aalto
Juha-Matti Aalto
MPMia Pirskanen
Mia Pirskanen
JKJari Kaikkonen
Jari Kaikkonen
ADAriel Darvasi
Ariel Darvasi

9 March 2001 in Diabetologia
Verified
Journal Article
Closed access
PDF file
AHA. H. Heald
A. H. Heald
JCJ. K. Cruickshank
J. K. Cruickshank
LRL. K. Riste
L. K. Riste
JCJanet Cade
Janet Cade
SASimon Anderson
Simon Anderson
JGJ. M. Gibson
J. M. Gibson

11 October 2005 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RMRachel J. Middleton
Rachel J. Middleton
RFRobert N. Foley
Robert N. Foley
JHJanet Hegarty
Janet Hegarty
CCChing M. Cheung
Ching M. Cheung
PMPatrick McElduff
Patrick McElduff
JNJohn P. New
John P. New
Background. Diabetes mellitus and chronic kidney disease (CKD) are common and exhibit synergistic associations with premature mortality. Current diabetes guidelines in the UK recommend annual urinary albumin and serum creatinine determinations to screen for diabetic kidney disease. The aim of this study was to estimate the burden of CKD in patients with diabetes and examine the ability of serum creatinine and albuminuria to detect clinically meaningful CKD compared with estimated glomerular filtration rate (eGFR). Methods. All adults known to have diabetes in primary and secondary care in Salford, UK, alive with independent renal function on 1 January 2004 were included in this observational study (n = 7596). Demographic and laboratory parameters were obtained from the Electronic Patient Record. eGFR was determined using the 4-variable modification of diet in renal disease (MDRD) formula. Clinically meaningful CKD was defined as an eGFR <60 ml/min/1.73 m2. Results. Creatinine and albuminuria were measured in the preceding 2 years in 82.3 and 55.2% of subjects, respectively. In patients with CKD, normoalbuminuria was present in 48.8%, and serum creatinine was normal (≤120 µmol/l) in 54.7%. An abnormal serum creatinine (≥120 µmol/l) had a sensitivity and specificity of 45.3 and 100%, respectively, to identify CKD. The combination of abnormal creatinine and albuminuria had an improved performance but still failed to detect a large number with CKD (sensitivity 82.4%, specificity 75.4%). Serum creatinine failed to identify CKD more often in females (OR 8.22, CI 6.56–10.29). Conclusions. Undiagnosed CKD is common in diabetes. Current screening strategies, based on creatinine or albuminuria, fail to identify a considerable number of subjects with CKD. Incorporating eGFR into screening for CKD would identify individuals earlier in the natural history of the disease and enable early effective treatment to delay progression of CKD.

1 August 2003 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
JNJohn P. New
John P. New
JMJames M. Mason
James M. Mason
NFNick Freemantle
Nick Freemantle
STSue Teasdale
Sue Teasdale
LWLouise M. Wong
Louise M. Wong
JGJohn M. Gibson
John M. Gibson
OBJECTIVE—To determine the effectiveness of specialist nurse-led clinics for hypertension and hyperlipidemia provided for diabetic patients receiving hospital-based care. RESEARCH DESIGN AND METHODS—This study was a randomized controlled implementation trial at Hope Hospital, Salford, U.K. The subjects consisted of 1,407 subjects presenting for annual review with raised blood pressure (≥140/80 mmHg), raised total cholesterol (≥5.0 mmol/l), or both. Individuals with diabetes were randomized to usual care or usual care with subsequent invitation to attend specialist nurse-led clinics. Nurses provided clinics for participants, with attendance every 4–6 weeks, until targets were achieved. Lifestyle advice and titration of drug therapies were provided according to the locally agreed upon guidelines. Patients with both conditions were eligible for enrollment in either or both clinics. At subsequent annual review, blood pressure and total cholesterol values were obtained from the Salford electronic diabetes register. Data relating to deaths were obtained from the national strategic tracing service. The primary outcome was the odds ratio of achieving targets in hypertension and hyperlipidemia, attributable to the specialist nurse-led intervention. RESULTS—Overall, specialist nurse-led clinics were associated with a significant improvement in patients achieving the target after 1 year (odds ratio [OR] 1.37 [95% CI 1.11–1.69], P = 0.003). This primary analysis revealed a borderline difference in effect between the two types of clinics (test for interaction between groups: P = 0.06). Secondary analysis, consistent with the prior beliefs of the health care professionals involved, suggested that targets were achieved more frequently in patients enrolled in the specialist nurse-led clinic for hyperlipidemia (OR 1.69 [1.25–2.29], P = 0.0007) than for hypertension (OR 1.14 [0.86–1.51], P = 0.37). Intervention (enrolled to either or both clinics) was associated with a reduction in all-cause mortality (OR 0.55 [0.32–0.92], P = 0.02). CONCLUSIONS—This study provides good evidence to support the use of specialist nurse-led clinics as an effective adjunct to hospital-based care of patients with diabetes. If the standards of care recommended in the National Service Framework for Diabetes are to be achieved, then such proven methods for delivering care must be adopted.